# US 2016/0257657 A1 · Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257657 A1
- Document ID: US20160257657A1
- Status: Published application
- Kind: A1
- Application number: 15/080,237
- Filed: 2016-03-24
- Published: 2016-09-08
- Earliest claimed: 2013-09-20
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education
- Inventors: Peter Wipf; James K. Johnson; Erin M. Skoda; Joel B. Nelson; Zhou Wang
- Web page: https://patentgrep.com/patent/US20160257657A1

## CPC

- C07D 261/08: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A61K 31/4166: having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A61K 31/42: Oxazoles
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/46: 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 295/185: from aliphatic carboxylic acids
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 451/00: Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A compound, or a pharmaceutically acceptable salt or ester thereof, according to formula I: R20—(Z)b—(Y)c—(R21)a—(X)d—R22—R23 wherein R20 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; Z is alkanediyl, substituted alkanediyl, cycloalkanediyl, or substituted cycloalkanediyl; Y is S, O, S(═O), —S(═O)(═O)—, or NR10, wherein R10 is H or alkyl; R21 is alkanediyl, substituted alkanediyl, cycloalkanediyl, substituted cycloalkanediyl alkadienyl, substituted alkadienyl, alkatrienyl, substituted alkatrienyl; X is —C(═O)—, —S(═O)(═O)—, or —N(H)C(═O)—; R22 includes at least one divalent amino radical; R23 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; a, b, c, and d independently are 0 or 1.

## Claims

### Claim 1

A compound, or a pharmaceutically acceptable salt or ester thereof, selected from:

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is:

### Claim 3 (depends on 1)

The compound of claim 1, wherein the compound is:

### Claim 4 (depends on 1)

The compound of claim 1, wherein the compound is:

### Claim 5 (depends on 1)

A pharmaceutical composition comprising at least one pharmaceutically acceptable additive, and a compound of claim 1.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, wherein the compound is:

### Claim 7 (depends on 5)

The pharmaceutical composition of claim 5, wherein the compound is:

### Claim 8 (depends on 5)

The pharmaceutical composition of claim 5, wherein the compound is:

### Claim 9 (depends on 1)

A method for treating prostate cancer in a subject, comprising administering to the subject a therapeutically effective amount of a compound of claim 1.

### Claim 10 (depends on 9)

The method of claim 9, wherein the prostate cancer is castration-resistant prostate cancer.

### Claim 11 (depends on 9)

The method of claim 9, wherein the compound is orally administered.

### Claim 12 (depends on 9)

The method of claim 9, wherein the method is used in combination with androgen deprivation therapy.

### Claim 13 (depends on 9)

The method of claim 9, wherein the agent is co-administered with abiratrone.

### Claim 14 (depends on 9)

The method of claim 9, wherein the agent is co-administered with enzalutamide.

### Claim 15 (depends on 9)

The method of claim 9, wherein the method further comprises identifying a subject that is in need of treatment with the agent.

### Claim 16 (depends on 9)

The method of claim 9, wherein the compound is:

### Claim 17 (depends on 9)

The method of claim 9, wherein the compound is:

### Claim 18 (depends on 9)

The method of claim 9, wherein the compound is:
